Item 9A. Controls and Procedures
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of January 31, 2025. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of January 31, 2025, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified by Securities and Exchange Commission (“SEC”) rules and forms and (b) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the criteria set forth in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management has concluded that its internal control over financial reporting was effective as of January 31, 2025 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. The effectiveness of our internal control over financial reporting as of January 31, 2025, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears in Part II, Item 8 of this Annual Report on Form 10-K.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) under the Exchange Act during the fourth quarter of fiscal 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Docusign, Inc. | 2025 Form 10-K | 99
ITEM 9B. OTHER INFORMATION
During the three months ended January 31, 2025, none of the officers or directors of the Company entered into trading plans intended to satisfy the affirmative defense of Rule 10b5-1 (c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies on insider trading.
On November 26, 2024 , Daniel Springer , a member of our board of directors , terminated his 10b5-1 trading plan that had been adopted on April 8, 2024 and was scheduled to expire on April 9, 2025. The adoption of this 10b5-1 trading plan occurred during an open insider trading window. The adoption and subsequent termination of the plan complied with the Company’s policies on insider trading.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
None.
Docusign, Inc. | 2025 Form 10-K | 100
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Code of Conduct
We maintain a Code of Conduct applicable to all of our employees, including our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer, which is a “Code of Ethics for Senior Financial Officers” as defined by applicable rules of the SEC. This code is publicly available on our investor relations website at investor.docusign.com. If we make any amendments to this code other than technical, administrative or other non-substantive amendments, or grant any waivers, including implicit waivers, from a provision of this code we will disclose the nature of the amendment or waiver, its effective date and to whom it applies on our investor relations website or in a Current Report on Form 8-K filed with the SEC.
Insider Trading Policy
We have adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of our securities by directors, officers and employees. Our Insider Trading Policy also provides that we will not transact in any of our own securities unless in compliance with U.S. securities laws. We believe that our Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the Nasdaq listing standards applicable to us. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K.
The remaining information required by this item, including information about our Directors, Executive Officers and Audit Committee, is incorporated by reference to the definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, which will be filed with the SEC no later than 120 days after January 31, 2025.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, which will be filed with the SEC no later than 120 days after January 31, 2025.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, which will be filed with the SEC no later than 120 days after January 31, 2025.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, which will be filed with the SEC no later than 120 days after January 31, 2025.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this item is incorporated by reference to the definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, which will be filed with the SEC no later than 120 days after January 31, 2025.
Docusign, Inc. | 2025 Form 10-K | 101
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) Documents filed as a part of this Annual Report on Form 10-K:
1. Financial Statements
The following financial statements are included in Part II, Item 8 of this Annual Report on Form 10-K:
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive Income (Loss)
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
2. Financial Statement Schedules
All other schedules have been omitted because they are not required, not applicable, or the required information is otherwise included.
3. Exhibits
See the Exhibit Index immediately following "Item 16. Form 10-K Summary."
Docusign, Inc. | 2025 Form 10-K | 102
ITEM 16. FORM 10-K SUMMARY
None.
EXHIBIT INDEX
Exhibit Number Description Form File No. Incorporated by Reference Exhibit Filing Date
3.1 Amended and Restated Certificate of Incorporation .
8-K 001-38465 3.1 May 1, 2018
3.2 Amended and Restated Bylaws.
8-K
001-38465
3.1 March 11, 2024
4.1 Form of Common Stock Certificate .
S-1/A 333-223990 4.1 April 17, 2018
4.2 Credit Agreement, dated as of January 11, 2021, by and among the Registrant, Bank of America, N.A., BofA Securities, Inc. and Silicon Valley Bank, and the lenders thereunder.
8-K 001-38465 99.1 January 11, 2021
4.3 First Amendment to Credit Agreement, dated as of May 26, 2023, by and among the Registrant, Bank of America, N.A., BofA Securities, Inc. and First-Citizens Bank & Trust, and the lenders thereunder.
10-Q
001-38465 4.1 June 8, 2023
4.7 Description of the Registrant's Securities.
10-K 001-38465 4.8 March 31, 2021
10.1 Form of Indemnity Agreement between the Registrant and each of its directors and executive officers .
8-K 001-38465 10.1 December 3, 2020
10.2#
Amended and Restated 2011 Equity Incentive Plan, as amended.
S-1 333-223990 10.2 March 28, 2018
10.3#
Form of Option Agreement and Exercise Notice under Amended and Restated 2011 Equity Incentive Plan .
S-1 333-223990 10.3 March 28, 2018
10.4#
Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under Amended and Restated 2011 Equity Incentive Plan .
S-1 333-223990 10.4 March 28, 2018
10.5#
2018 Equity Incentive Plan.
S-8 333-224577 10.6 May 1, 2018
10.6#
Form of Option Agreement and Exercise Notice under 2018 Equity Incentive Plan .
S-1 333-223990 10.6 March 28, 2018
10.7#
Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under 2018 Equity Incentive Plan .
S-1 333-223990 10.7 March 28, 2018
10.8#
2018 Employee Stock Purchase Plan.
S-8 333-224577 10.9 May 1, 2018
10.9#
Form of Performance Stock Unit Grant Notice under 2018 Equity Incentive Plan.
10-Q 001-38465 10.5 June 9, 2022
10.10 Office Lease 221 Main Street and related amendments .
S-1 333-223990 10.12 March 28, 2018
10.11 11th Amendment to Office Lease 221 Main Street.
10-K
001-38465 10.12
March 27, 2023
10.12#
Non-Employee Director Compensation Policy, amended and restated as of August 29, 2023.
10-Q
001-38465 10.1 September 7, 2023
10.13#
Offer Letter dated September 13, 2022 by and between the Registrant and Allan Thygesen.
8-K 001-38465 10.1 September 22, 2022
10.14#
Offer Letter, dated as of May 3 , 2022, by and between the Registrant and James Shaughnessy.
10-Q
001-38465 10.2
June 9, 2022
10.16#
Offer Letter, dated as of January 3, 2023, by and between the Registrant and Robert Chatwani.
8-K 001-38465 10.2 March 10, 2023
10.17#
Offer Letter, dated as of April 26, 2023, by and between the Registrant and Blake Grayson.
8-K 001-38465 10.1 May 16, 2023
Docusign, Inc. | 2025 Form 10-K | 103
10.18#
O ffer Letter, dated as of June 7, 2024, by and between the R egistrant and Paula Hansen .
8-K 001-38465 10.2
June 25, 2024
10.19#
Form of Amended and Restated Executive Severance and Change in Control Agreement.
8-K 001-38465 10.1
January 17, 2025
10.20#
E xecutive Severance and Change in Control Agreement, dat ed as of June 10, 2024, by and between the R egistrant and Paula Hansen.
8-K 001-38465 10.3
June 25, 2024
10.21#
E xecutive Severance and Change in Control Agreement, dates as of February 4, 2025, by and between the Registrant and Blake Grayson.
Filed herewith
19.1†
I nsider Trading Policy
Filed herewith
21.1 Subsidiaries of the Registrant.
Filed herewith
23.1 Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
Filed herewith
24.1 Power of Attorney (reference is made to the signature page hereto). Filed herewith
31.1 Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Filed herewith
31.2 Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Filed herewith
32.1* Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Filed herewith
97.1 Compensation Recovery (Clawback) Policy, adopted November 28, 2023.
10-K
001-38465 97.1
March 21, 2024
101.INS Inline XBRL Instance Document. Filed herewith
101.SCH Inline XBRL Taxonomy Extension Schema Document. Filed herewith
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. Filed herewith
101.DEF Inline XBRL Taxonomy Definition Linkbase Document. Filed herewith
101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document. Filed herewith
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. Filed herewith
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) Filed herewith
* The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.
# Indicates management contract or compensatory plan, contract or agreement.
†
We have omitted the schedules or exhibits to this Exhibit in accordance with Regulation S-K Item 601(a)(5). A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon its request.
Docusign, Inc. | 2025 Form 10-K | 104
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 18, 2025
DOCUSIGN, INC.
By: /s/ Allan Thygesen
Allan Thygesen
Chief Executive Officer
(Principal Executive Officer)
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Allan Thygesen and Blake Grayson, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.
Docusign, Inc. | 2025 Form 10-K | 105
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
Signature Title Date
/s/ Allan Thygesen Chief Executive Officer and Director March 18, 2025
Allan Thygesen ( Principal Executive Officer )
/s/ Blake Grayson
Chief Financial Officer March 18, 2025
Blake Grayson
( Principal Accounting and Financial Officer )
/s/ Mary Agnes Wilderotter Chair, Director March 18, 2025
Mary Agnes Wilderotter
/s/ James Beer Director March 18, 2025
James Beer
/s/ Teresa Briggs Director March 18, 2025
Teresa Briggs
/s/ Cain A. Hayes Director March 18, 2025
Cain A. Hayes
/s/ Blake J. Irving Director March 18, 2025
Blake J. Irving
/s/ Anna Marrs
Director March 18, 2025
Anna Marrs
/s/ Enrique T. Salem Director March 18, 2025
Enrique T. Salem
/s/ Peter Solvik Director March 18, 2025
Peter Solvik
/s/ Daniel D. Springer Director March 18, 2025
Daniel D. Springer
Docusign, Inc. | 2025 Form 10-K | 106